Begin screening and patient enrollment for AMT-260
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Oct 2023
- Due
- 31 Dec 2023
- Checked
- 4 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Screening and patient enrollment is expected to begin in the fourth quarter of 2023”
What we found
Evidence strength A What the grades mean
uniQure committed to begin AMT-260 screening and enrollment in Q4 2023 but revised timeline in February 2024 to first half of 2024; first patient dosed November 2024.
-
A uniQure N.V. - Form 8-K - October 2023
“Screening and patient enrollment is expected to begin in the fourth quarter of 2023 with first patient dosing occurring in the first quarter of 2024.” ✓ confirmed on the page
-
A uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial
“November 21, 2024 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the GenTLE Phase I/IIa clinical trial of AMT-260” ✓ confirmed on the page
-
B uniQure Announces 2023 Financial Results
“Site initiation is underway, and patient enrollment is expected to begin in the first half of 2024.”
Checked 4 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- AMT-260 screening and enrollment
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-QURE-001852 · Corrections policy